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Abstract
Opiates, like other addictive drugs, elevate forebrain dopamine levels and are thought to do so mainly by inhibiting GABA
neurons near the ventral tegmental area (VTA), in turn leading to a disinhibition of dopamine neurons. However, cholinergic
inputs from the laterodorsal (LDT) and pedunculopontine (PPT) tegmental nucleus to the VTA and substantia nigra (SN)
importantly contribute, as either LDT or PPT lesions strongly attenuate morphine-induced forebrain dopamine elevations.
Pharmacological blockade of muscarinic acetylcholine receptors in the VTA or SN has similar effects. M5 muscarinic
receptors are the only muscarinic receptor subtype associated with VTA and SN dopamine neurons. Here we tested the
contribution of M5 muscarinic receptors to morphine-induced dopamine elevations by measuring nucleus accumbens
dopamine efflux in response to intra-VTA morphine infusion using in vivo chronoamperometry. Intra-VTA morphine
increased nucleus accumbens dopamine efflux in urethane-anesthetized wildtype mice starting at 10 min after infusion.
These increases were absent in M5 knockout mice and were similarly blocked by pre-treatment with VTA scopolamine in
wildtype mice. Furthermore, in wildtype mice electrical stimulation of the PPT evoked an initial, short-lasting increase in
striatal dopamine efflux, followed 5 min later by a second prolonged increase in dopamine efflux. In M5 knockout mice, or
following systemic pre-treatment with scopolamine in wildtype mice, the prolonged increase in striatal dopamine efflux was
absent. The time course of increased accumbal dopamine efflux in wildtype mice following VTA morphine was consistent
with both the prolonged M5-mediated excitation of striatal dopamine efflux following PPT electrical stimulation and
accumbal dopamine efflux following LDT electrical stimulation. Therefore, M5 receptors appear critical for prolonged PPT
excitation of dopamine efflux and for dopamine efflux induced by intra-VTA morphine.
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Introduction
Dopamine neurotransmission in the forebrain plays an
important role in the reinforcing effects of drugs of abuse [1].
Opiate drugs like heroin and morphine are thought to affect
dopaminergic neurotransmission through their actions near the
ventral tegmental area (VTA), where opiates inhibit local gamma-
aminobutyric acid (GABA) neurons by acting on mu opioid
receptors [2], leading to increased firing of dopamine neurons via
disinhibition [3–4], and increased accumbal dopamine [5–6].
Opiate-induced dopamine elevations in the forebrain also
depend, however, on cholinergic inputs from the pedunculopon-
tine (PPT) and laterodorsal (LDT) tegmental nuclei that excite
midbrain dopamine neurons [7–8]. In rats, PPT or LDT lesions
reduce most of the striatal or accumbal dopamine increases
following systemic morphine [9–10]. Additionally, VTA or SN
infusions of the non-selective muscarinic receptor antagonist
scopolamine similarly reduce most striatal or accumbal dopamine
increases following systemic morphine [11]. PPT lesions also block
morphine place preference [12] and heroin self-administration
[13] in drug-naı ¨ve rats. The pathways through which the PPT
mediates the acute rewarding effects of opiates and dopamine
activation (i.e., via descending or ascending projections) are not
clear, but cholinergic mechanisms are important. For example,
intra-VTA infusion of the muscarinic antagonist atropine reduces
morphine place preference in rats [14].
The M5 muscarinic acetylcholine receptor subtype, associated
with dopamine neurons, is most important for cholinergic
excitation of VTA and SN dopamine neurons [15–19]. In mice,
for example, accumbal dopamine efflux following LDT electrical
stimulation occurs in three phases. The strongest dopamine efflux
in the long third phase is absent in M5 knockout mice [19].
M5 muscarinic excitation is also critical for opiate functions.
M5 knockout mice show reduced morphine-induced accumbal
dopamine efflux as measured by microdialysis, and reduced
morphine conditioned place preference [20]. Also, morphine-
induced locomotion is reduced by ,40–50% in M5 knockout
mice [21]. M5 muscarinic receptors in the VTA, therefore,
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27538contribute strongly to both the stimulant and rewarding effects of
morphine.
The goal of the current studies was to better understand the role
of the PPT and M5 receptors in opiate-induced dopamine
activation. Increases in accumbal dopamine efflux following
VTA infusions of morphine were absent in M5 knockout mice.
Prolonged PPT-evoked striatal dopamine efflux, which has not
been previously characterized in mice, was also reduced in M5
knockout mice. In both cases, M5-mediated increases in forebrain
dopamine efflux followed a similar time course. Our results suggest
that VTA opiates may indirectly activate dopamine neurons
through a mechanism involving a PPT/LDT cholinergic relay.
Results
Experiment 1: Intra-VTA morphine-induced accumbal
dopamine efflux in wildtype and M5 knockout mice
Histology. Figure 1A shows VTA injection sites identified
from brains of individual wildtype and M5 knockout mice in
Experiment 1. Injection sites in the various treatment conditions
were confined within the boundaries of the VTA and were spread
along its rostro-caudal extent. Recording sites in the nucleus
accumbens (Fig. 1B) were confined to the core region between
0.98 and 1.54 mm anterior to bregma. Only mice with both VTA
injection and accumbens recording sites were used for statistical
analysis.
VTA morphine increases accumbal dopamine efflux in
wildtype, but not in M5 knockout, mice. Compared to
saline, intra-VTA infusions of morphine (50 ng) in wildtype mice
induced a delayed increase in accumbal dopamine efflux that
began 16.567.9 min after infusion and steadily increased over the
course of the following 2 hrs. Subsequently, dopamine efflux
leveled off over a 50-min period, but never decreased back to
baseline levels (Fig. 2A). By contrast, in M5 knockout mice the
same dose of intra-VTA morphine induced a slight decrease in
accumbal dopamine efflux relative to saline, starting at
5.962.0 min, that returned to pre-injection baseline levels by
92.069.8 min and subsequently showed a slight increase to above
baseline over the final 30 min (Fig. 2B).
A between-within repeated-measures ANOVA with genotype as
the between-subjects factor and time as the within-subjects factor
revealed a significant interaction between genotype and time (F
(344, 1376)=11.59, p,0.0001), confirming that the temporal
profile of accumbal dopamine efflux induced by intra-VTA
morphine was different between wildtype and M5 knockout mice.
Post-hoc analysis using Fischer’s LSD test showed significantly
lower accumbal dopamine efflux in M5 knockout mice at every 30-
sec time point between 32 and 165 min (p’s,0.05 to p’s,0.001).
VTA scopolamine prevents increases in accumbal
dopamine efflux induced by intra-VTA morphine in
wildtype mice. In wildtype mice, intra-VTA pre-treatment
with scopolamine (50 mg) prevented the increase in accumbal
dopamine efflux typically observed following intra-VTA morphine
(50 ng) (Fig. 2C). Most interestingly, the intra-VTA combination
of scopolamine and morphine in wildtype mice resulted in a
decrease in accumbal dopamine efflux, comparable to that
observed following intra-VTA morphine alone in M5 knockout
mice (Fig. 2B vs. 2C). A two-way between-within repeated-
measures ANOVA with drug pre-treatment in wildtype mice
(VTA scopolamine vs. no pre-treatment) as the between-subjects
factor and time as the within-subjects factor revealed a significant
interaction between pre-treatment and time, F (306, 2448)
=11.22, p,0.000001, indicating that the temporal profile of
dopamine efflux varied as a function of VTA pre-treatment. Post-
hoc analysis using Fischer’s LSD test showed that scopolamine
pre-treatment significantly reduced accumbal dopamine efflux at
every 30-sec time point between 40 and 165 min (all p’s,0.05).
Increased accumbal dopamine efflux induced by intra-
VTA morphine is prevented by systemic naltrexone in
wildtype mice. Figure 2D shows accumbal dopamine efflux
induced by intra-VTA morphine (50 ng) in wildtype mice that
were pre-treated with systemic naltrexone (1 mg/kg i.p.). VTA
morphine infusion delivered 5 min after systemic naltrexone
resulted in a decrease in accumbal dopamine efflux to below
baseline levels that peaked at 33.764.7 min and returned to pre-
injection baseline levels by 57.869.3 min. Over the course of the
next 1.5 hrs, accumbal dopamine efflux gradually increased but
always remained below levels observed in VTA morphine-infused
wildtype mice that were not pre-treated with naltrexone. Thus,
systemic naltrexone pre-treatment effectively blocked the steady
morphine-induced increase observed in wildtype mice starting
between 10–20 min, but was unable to block a small increase in
dopamine efflux starting at approximately 1 hr. A two-way
between-within repeated measures ANOVA with group
(naltrexone pre-treatment vs. no pre-treatment) as the between-
subjects factor and time as the within-subjects factor revealed a
significant interaction between group and time (F (305,
1830)=3.01, p,0.00001). This indicates that the temporal
profile of accumbal dopamine efflux across the 2.5-hr recording
period was different between mice pre-treated with naltrexone and
mice that received no pre-treatment. Post-hoc analysis using
Fischer’s LSD test showed significantly reduced accumbal
dopamine efflux in mice pre-treated with naltrexone at every 30-
sec time point between 54 and 148 min (all p’s,0.05).
Experiment 2: PPT-evoked striatal dopamine efflux in
wildtype and M5 knockout mice
Histology. PPT stimulating electrodes in both wildtype and
M5 knockout mice were distributed along the rostro-caudal extent
of the PPT as shown on sagittal sections (Fig. 3A). Recording
electrodes were confined within the boundaries of the striatum,
between 0.98–1.70 mm anterior to bregma in both wildtype and
M5 knockout mice (Fig. 3B). At the current used in these
experiments, the stimulation was estimated to activate
unmyelinated PPT cholinergic axons (conduction velocities of
0.4–1.2 m/s) within a distance of 0.75 mm of the electrode tip
[22–23].
M5 knockout mice show reduced PPT-evoked striatal
dopamine efflux. Electrical stimulation of the PPT in wildtype
mice induced two increases in striatal dopamine efflux separated
by a trough near 5 min post-stimulation. The first increase began
with the first measurement at 30 sec after stimulation and peaked
at a mean of 1.25 min (Fig. 4A, black line and Table 1). This was
followed by a more gradual decline in dopamine efflux (trough)
that reached a minimum at 4.25 min. At ,5–6 min after PPT
stimulation, dopamine efflux began to increase again (second
increase). This second increase peaked at 33 min and had a mean
duration of 68.163.7 min, as measured by the time from the
trough minimum to the time the signal returned to pre-stimulation
baseline levels. This second increase was ,3.4 times larger than
the first increase in dopamine efflux and over 30 times longer in
duration.
PPT stimulation in M5 knockout mice also induced two
increases in striatal dopamine efflux separated by a trough
(Fig. 4A, gray line and Table 1). Neither the magnitude nor the
time of the first increase or the subsequent trough in striatal
dopamine efflux differed significantly between M5 knockout and
wildtype mice (all p’s.0.1). By comparison however, the second
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dopamine efflux significantly lower compared to wildtype mice
(t(14)=3.38, p,0.01). The minimum of the trough was always
above baseline in both wildtype and M5 knockout mice.
To calculate the overall M5 contribution to PPT-evoked striatal
dopamine efflux, the average PPT-evoked change in basal
dopamine oxidation current in M5 knockout mice was subtracted
from the average change in wildtype mice. This shows that
following electrical stimulation of the PPT, M5 receptors mediate a
delayed increase in striatal dopamine efflux with the greatest rise
occurring between 5 and 22 min, and a peak around 30 min
(Fig. 4B). This delayed M5 contribution is consistent with previous
studies measuring M5 time course in pilocarpine-induced
salivation and in N-methyl-scopolamine binding studies in vitro
[24–25].
Systemic scopolamine pre-treatment reduces striatal
dopamine efflux in wildtype, but not in M5 knockout,
mice. In wildtype mice, systemic administration of
scopolamine 30 min prior to PPT stimulation did not alter the
magnitude (t(3)=1.00, p.0.3), or the time (t(3)=0.39, p.0.7)
of the first increase in striatal dopamine efflux. The trough was
slightly enhanced, with the minimum now below baseline,
resulting in a statistically significant difference relative to the
pre-scopolamine baseline (t(3)=3.94, p,0.05). Pre-treatment
with scopolamine almost completely abolished the second
increase in striatal dopamine efflux (t(3)=7.53, p,0.01) in
wildtype mice (Fig. 4C).
In M5 knockout mice (Fig. 4D), systemic administration of
scopolamine 30 min prior to PPT stimulation did not affect the
magnitude (p.0.5) or the time (p.0.5) of the first increase in
striatal dopamine efflux. The trough was also not affected in M5
knockout mice, either in terms of its minimum (p.0.4) or the time
of the minimum (p.0.2). Scopolamine had no effect on the
already significantly reduced second increase in dopamine efflux in
M5 knockout mice (p.0.9).
Discussion
Increases in accumbal dopamine efflux following intra-VTA
morphine were absent in M5 knockout mice and blocked by VTA
scopolamine pre-treatment in wildtype mice. In a similar manner,
the second increase in striatal dopamine efflux following electrical
stimulation of the PPT was absent in M5 knockout mice and
blocked by systemic scopolamine pre-treatment in wildtype mice.
In both cases M5 receptors mediated a delayed onset, prolonged
increase in accumbal and striatal dopamine efflux. Together, these
data suggest that M5 receptor activation in the VTA/SN is critical
for delayed, long-lasting excitation of dopamine neurons by either
intra-VTA morphine or PPT electrical stimulation.
In wildtype mice, morphine infusion into the VTA induced a
slow and long-lasting (.2 hrs) increase in accumbal dopamine
efflux that began 10–20 min after infusion. This effect was entirely
absent in M5 knockout mice. By contrast, nicotine or carbachol in
rats has been shown to increase basal dopamine efflux in the
accumbens within 1 min following VTA infusion [8,26–27],
indicating a 10–20 min delay in the activation of dopamine
neurons by VTA morphine and consequent detectable increases in
accumbal dopamine efflux.
Figure 1. VTA injection sites (A) and nucleus accumbens
recording sites (B) used in Experiment 1. In both (A) and (B),
open circles show placements from M5 knockout mice (n=4) treated
with 50 ng intra-VTA morphine, closed circles show placements from
M5 knockout mice treated with 0.3 ml intra-VTA saline (n=4), open
triangles show placements from wildtype mice (n=4) treated with
50 ng intra-VTA morphine, closed triangles show placements from
wildtype mice (n=4) treated with 0.3 ml intra-VTA saline, stars show
placements from wildtype mice (n=6) pre-treated with 50 mg intra-VTA
scopolamine followed by 50 ng intra-VTA morphine, and open squares
show placements from wildtype mice (n=4) pre-treated with 1 mg/kg
(i.p.) naltrexone followed by 50 ng intra-VTA morphine. For clarity
infusion sites are shown on both left and right side of the brain, but VTA
infusions were always made on the left side of the brain. Numbers to
the left of or above individual sections show distance in mm from
bregma. Sections were adapted from the atlas of Paxinos and Franklin
[38].
doi:10.1371/journal.pone.0027538.g001
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following VTA morphine infusion and then leveled off between
2.5 to 3 hrs post-infusion. Previous chronoamperometric mea-
surement of both i.v. morphine-induced accumbal and striatal
dopamine efflux in urethane-anesthetized rats using similar
recording electrodes showed a shorter-latency increase in
dopamine efflux that peaked at ,40 min and fully returned to
pre-injection baseline levels between 2–3 hours [9–11]. Similarly,
morphine-induced accumbal dopamine efflux measured by
microdialysis in mice showed a peak between 60 and 80 min that
gradually returned toward baseline between 2.5–3 hrs [20,28].
Figure 3. PPT stimulation sites (A) and striatal recording sites
(B) used in Experiment 2. (A) Sagittal sections of the mouse brain
showing tip placements of PPT stimulating electrodes in wildtype (open
triangles, n=7) and M5 knockout (open circles, n=7) mice. Numbers
above individual sections indicate lateral distance in mm from the
midline. (B) Coronal sections of the mouse brain showing tip
placements of recording electrodes in wildtype (open triangles, n=7)
and M5 knockout (open circles, n=7) mice. Numbers above individual
sections show distance in mm from bregma. Sections are adapted from
the atlas of Paxinos and Franklin [38].
doi:10.1371/journal.pone.0027538.g003
Figure 2. Changes in accumbal dopamine efflux produced by
50 ng intra-VTA morphine or saline in wildtype (+/+)o rM 5
knockout (2/2) mice. In all cases, thick lines represent mean
dopamine oxidation current across mice, and thin lines represent
6SEM. (A) Mean change in accumbal dopamine efflux in wildtype mice
following 50 ng intra-VTA morphine (black line, n=4) or 0.3 ml intra-
VTA saline (gray line, n=4). (B) Mean change in accumbal dopamine
efflux in M5 knockout mice following 50 ng intra-VTA morphine (black
line, n=4) or 0.3 ml intra-VTA saline (gray line, n=4). (C) Effects of pre-
treatment with 50 mg intra-VTA scopolamine on accumbal dopamine
efflux induced by 50 ng intra-VTA morphine in wildtype mice (black
line, n=6). For comparison, data from (A) showing mean changes in
accumbal dopamine efflux induced by 50 ng intra-VTA morphine
without any pre-treatment in wildtype mice are reproduced (gray line,
n=4). (D) Effects of pre-treatment with naltrexone (1 mg/kg, i.p.) 5 min
prior to 50 ng intra-VTA morphine in wildtype mice (black line, n=4).
For comparison, data from (A) showing mean changes in accumbal
dopamine efflux induced by 50 ng intra-VTA morphine without any
pre-treatment in wildtype mice are reproduced (gray line, n=4).
doi:10.1371/journal.pone.0027538.g002
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intra-VTA morphine observed in urethane-anesthetized mice is
thought to have functional relevance, as mice self-administer a
50 ng dose of morphine into the VTA, and this self-administration
has been shown to be reduced by pre-treatment with 4 mg/kg
(i.p.) of the non-selective opioid receptor antagonist naloxone [29].
In a similar manner, we observed a marked reduction in the
increase in accumbal dopamine efflux following pre-treatment
with 1 mg/kg (i.p.) naltrexone. As morphine was infused directly
into the VTA, it is likely that systemic naltrexone inhibited
increases in dopamine efflux via blockade of VTA opioid
receptors. Although naltrexone pre-treatment completely blocked
morphine-induced accumbal dopamine efflux for the first 60 min,
dopamine efflux recovered to above baseline levels over the course
of the next 90 min (see Fig. 2D). Interestingly, pre-treatment with
1 mg/kg naltrexone in B6 wildtype mice has been shown to
completely block morphine-induced locomotion (30 mg/kg, i.p.)
for the first 90 min, but over the final 30 min of testing locomotor
levels increase [21]. Thus, opioid receptors are likely responsible,
in a similar way, for both the effects of morphine on locomotion in
freely-behaving mice and on accumbal dopamine efflux induced
by intra-VTA morphine.
Our previous chronoamperometry study showed that electrical
stimulation of the LDT in wildtype mice evoked an initial brief
increase in accumbal dopamine efflux, followed by a brief decrease
to below baseline levels, and thereafter by a prolonged second
increase in accumbal dopamine efflux [19]. The present study
showed that electrical stimulation of the PPT in the same wildtype
mice also evoked two comparable increases in striatal dopamine
efflux. The first increase following PPT stimulation was not affected
in M5 knockout mice. The second, prolonged increase began 5–
6 min following stimulation, and in marked contrast to wildtype
mice,thesecondincreaseinstriataldopamineeffluxwassignificantly
reduced in M5 knockout mice. In addition, scopolamine pre-
treatment in wildtype mice prevented the second increase in striatal
dopamine efflux. Together, these data suggest that M5 receptors in
the SN [15–16] play a critical role in mediating sustained excitatory
cholinergic input to the nigrostriatal dopamine system.
The trough in striatal dopamine efflux following PPT
stimulation was reduced compared to LDT stimulation. Following
LDT stimulation in rats, the trough in accumbal dopamine has
been shown to be mediated by M2-like autoreceptors at the level of
the LDT [17]. The relatively smaller trough observed here in the
striatum suggests that these autoreceptors may not play a
significant role in regulating PPT cholinergic inputs to the SN
under the current conditions. In addition, the second increase in
PPT-evoked striatal dopamine efflux was much larger (,3.4-fold)
and faster (,5 min) relative to the first increase, compared to
LDT-evoked accumbal dopamine efflux (,2-fold and ,8 min)
described previously [19]. This suggests that the trough in PPT-
evoked striatal dopamine efflux in 129 wild-type mice is partly
masked by a larger M5-mediated second increase in prolonged
striatal dopamine efflux. Inspection of Figure 4B supports this as
the M5 contribution to increased striatal dopamine efflux following
PPT stimulation began during the trough (i.e. between 5 and
22 min), thus likely masking the inhibitory effect of the trough.
The temporal changes in dopamine efflux following PPT or
LDT stimulation provide several similarities to the effects of intra-
VTA morphine on accumbal dopamine efflux observed in
Experiment 1. Electrical stimulation of the PPT (Experiment 2)
increased striatal dopamine efflux with a relatively rapid onset
(,30 sec) followed by an M5 receptor-dependent increase in
dopamine efflux occurring ,5 min after stimulation (see Fig. 4B).
By comparison, intra-VTA morphine also increased accumbal
Figure 4. Striatal dopamine efflux following electrical stimula-
tion of the PPT in wildtype and M5 knockout mice. In all cases
thick lines represent mean oxidation current corresponding to striatal
dopamine efflux across mice, and thin lines represent 6 SEM. (A) PPT-
evoked striatal dopamine efflux in wildtype (black trace, n=7) and M5
knockout (gray trace, n=7) mice. (B) M5 receptor contribution to PPT-
evoked striatal dopamine efflux in mice. The graph shows the difference
in dopamine efflux between wildtype (n=7) and M5 knockout (n=7)
mice. (C) Effects of scopolamine (5 mg/kg, i.p.) pre-treatment on PPT-
evoked striatal dopamine efflux in 4 of the wildtype mice shown in (A).
The black trace shows PPT-evoked dopamine efflux, and the gray trace
shows PPT-evoked dopamine efflux following systemic scopolamine.
(D) Effects of scopolamine (5 mg/kg, i.p.) pre-treatment on PPT-evoked
striatal dopamine efflux in 4 of the M5 knockout mice shown in (A). The
black trace shows PPT-evoked dopamine efflux and the gray trace
shows PPT-evoked dopamine efflux following systemic scopolamine.
doi:10.1371/journal.pone.0027538.g004
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mice (Fig. 2A). If opiates in the VTA were affecting mesolimbic
dopamine neurons exclusively through disinhibition of local
GABA neurons [2], then elevations in basal extracellular
dopamine concentrations would be expected to occur faster than
10 min. Instead, the present data suggest that the 10-min onset
delay was due to opiate-induced disinhibition of PPT and LDT
cholinergic neurons, which, in turn, act more slowly on midbrain
dopamine neurons via M5 muscarinic receptors (see Fig. 4B).
Opiates can inhibit GABA neurons in the VTA [2] and
descending GABAergic projections to the PPT are important for
opiate reward in drug-naı ¨ve animals [30]. SN pars reticulata
GABA neurons have been shown to directly inhibit cholinergic
neurons in the pons [22] and whole-cell patch clamp recordings
have shown that cholinergic neurons in the LDT are inhibited by
GABA application [31]. Conceivably, inhibition of GABAergic
projections to the PPT and LDT by VTA opiates may, in turn,
lead to a disinhibition of ascending PPT/LDT cholinergic inputs
to the SN/VTA thereby enhancing dopamine neurotransmission
via activation of M5 receptors. The indirect activation of midbrain
dopamine neurons through a mesopontine cholinergic relay offers
an explanation for the delayed onset action of intra-VTA
morphine. This mechanism also explains the inability of intra-
VTA morphine to enhance basal accumbal dopamine efflux in M5
knockout mice, as well as the ability of intra-VTA scopolamine to
effectively block this increase in wildtype mice.
Our morphine infusions sites tended to be in the caudal half of
the VTA (Fig. 1A), so it is possible that the 0.3 ml infusions could
have spread to affect GABA neurons in the neighboring
rostromedial tegmentum (RMTg), where high levels of mu opioid
receptors are found [32]. Similar to the VTA, RMTg neurons can
be inhibited by morphine [33], and RMTg neurons project to,
among other places, the VTA and SNc, as well as the PPT [32].
In conclusion, the present data show that prolonged increases in
accumbal dopamine efflux induced by intra-VTA morphine, and
prolonged increases in striatal dopamine efflux induced by PPT
electrical stimulation both critically depend on M5 muscarinic
receptors in the midbrain. Consistent with previous studies [19–
20,34], the present data further emphasize the importance of M5
receptors in modulating cholinergic excitation of both nigrostriatal
and mesolimbic dopaminergic transmission. Previous studies have
shown that the PPT/LDT [9–10] and muscarinic receptors in the
SN/VTA [11] are critical for morphine-induced dopamine
activation. Here we show a complete loss of increased dopamine
efflux induced by intra-VTA morphine in M5 knockout mice.
Taken together, these data suggest an important role for increased
cholinergic input to the VTA in mediating dopamine activation
induced by morphine and specifically suggest that M5 receptors
are a critical target through which opiates in the VTA activate
mesencephalic dopaminergic systems.
Materials and Methods
Mice
M5 knockout mice were homozygous mutants for the M5
muscarinic acetylcholine receptor gene. Mice were created using
recombinant DNA methods on a mixed 129 SvJ6CD1 back-
ground as described by Takeuchi et al. [25]. Homozygous and
wildtype mice were used to maintain a colony based on
homozygous breeding. In all experiments litters of male homozy-
gous M5 knockout and wildtype mice were age-matched (4–8
months at the time of testing). Eighteen male wildtype and 8 male
M5 knockout mice were used in Experiment 1. Seven wildtype and
7M 5 knockout mice were used in Experiment 2. These studies
were approved by the University of Toronto Animal Care
Committee under protocol # 20007696.
Stearate-modified carbon-paste electrodes
Stearate-modified carbon paste electrodes were constructed
according to the methods of Blaha and Jung [35]. Briefly, 75 mg
of stearate (99.9% purity, Sigma-Aldrich, St. Louis, MO) were
dissolved in 1 ml silicone oil (Sigma-Aldrich, St. Louis, MO)
heated to 40uC. To this solution 1 g of graphite powder (particle
size ,20 mm, Sigma, St. Louis, MO) was added and thoroughly
mixed until reaching a paste-like consistency. Electrodes were
constructed by packing carbon paste into a 0.5–1 mm well,
created by extruding the Teflon coating off a 0.0080 o.d. Teflon-
coated stainless-steel wire (Medwire, Mount Vernon, NY) beyond
the tip of a ,10 cm length of wire. The carbon paste was packed
into the well tightly by dropping the electrode tip on a glass plate
several times. The surface of the electrode tip was investigated
under a microscope to ensure that there were no cracks or grooves
in the surface of the carbon paste.
Experiment 1: Morphine-induced accumbal dopamine
efflux in wildtype and M5 knockout mice
Surgery. Mice were anesthetized with urethane (1.5 g/kg,
i.p.). Each mouse was mounted in a stereotaxic frame (David Kopf
Table 1. Effects of PPT stimulation on dopamine oxidation current recorded from the striatum of wildtype (WT) and M5 knockout
(KO) mice before and after systemic administration of scopolamine (5 mg/kg, i.p.).
FIRST INCREASE TROUGH SECOND INCREASE
Group (n) Drug Peak Peak Minimum Minimum Peak Peak
(nA) Time (min) (nA) Time (min) (nA) Time (min)
WT (7) none 0.8660.2 1.2160.2 0.1760.3 4.1460.3 3.2460.5 34.1764.2
M5 KO (7) none 0.6860.2 1.5060.2 0.2660.1 4.560.2 0.6260.2* 27.3367.9
WT (4) none 0.7460.3 1.2560.4 0.1160.6 4.2560.4 3.8661.4 36.6265.8
WT (4) scopolamine 0.6360.3 1.1260.1 20.4360.1{ 4.7560.2 0.4560.1{ 38.62611
M5 KO (4) none 0.6960.3 1.7560.4 0.3660.2 4.6260.2 0.6260.4* 23.0063.2
M5 KO (4) scopolamine 0.6160.2 1.6260.6 0.4460.1 4.3760.6 0.6160.2 15.1363.5
*p,0.05 relative to wildtype control,
{p,0.05 relative to respective within-animal control.
doi:10.1371/journal.pone.0027538.t001
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rat earbars (Stoelting, Wood Dale, IL) and a mouse head-holder
(Stoelting, Wood Dale, IL). Temperature was maintained at
3760.5uC with a temperature-regulated heating pad (TC-1000;
CWE Inc., New York, NY). A single 26 gauge guide cannula
(Plastics One, Roanoke, VA) was implanted 1 mm dorsal to the
left VTA of each mouse (A/P +0.9 mm from lambda, M/L
0.4 mm D/V 24.4 mm from dura). For VTA infusions a 33
gauge cannula was inserted 1 mm past the tip of the guide
cannula, and was connected to a Hamilton microsyringe via
Tygon tubing. A single stearate-modified carbon paste recording
electrode was implanted into the left nucleus accumbens of each
mouse (A/P +1.4 mm from bregma, M/L 0.8 mm, D/V
23.6 mm from dura). A combination Ag/AgCl reference and
stainless-steel auxiliary electrode was placed into contact with the
contralateral parietal cortex.
Electrochemical recordings and VTA microinfu-
sions. After in vivo implantation of all electrodes and cannulae,
the working characteristics of the recording electrode were
evaluated by recording several voltammetric sweeps in the
striatum (triangular wave potentials applied from 20.15 to
0.45 V vs. Ag/AgCl; ramp rate 10–20 mV/sec) using an
electrometer (EChempro; GMA Technologies, Vancouver,
Canada). After confirming the presence of a dopamine peak in
the voltammogram, repetitive chronoamperometric measurements
of oxidation current were made by applying a potential pulse from
20.15 V to +0.25 V to the recording electrode for 1 sec at 30-sec
intervals and monitoring the current for the final 50 ms of each 1-
sec pulse [36]. Following at least 30 min of baseline recordings,
VTA infusions of morphine (50 ng, 0.3 ml volume) were made and
changes in accumbal dopamine oxidation current, corresponding
to dopamine efflux, were monitored for 2–3 hrs thereafter.
Changes in dopamine efflux following 50 ng intra-VTA
morphine were tested in 4 wildtype and 4 M5 knockout mice. In
an additional 6 wildtype mice, changes in accumbal dopamine
efflux in response to 50 ng intra-VTA morphine were measured
following VTA pre-treatment with 50 mg scopolamine 10 min
prior to morphine. Changes in accumbal dopamine efflux
following 50 ng intra-VTA morphine were also measured in an
additional 4 wildtype mice following systemic pre-treatment with
naltrexone hydrochloride (1 mg/kg, i.p.) 5 min prior to morphine.
Finally, changes in accumbal dopamine oxidation current in
response to 0.3 ml VTA saline were measured in 4 wildtype and 4
M5 knockout mice.
Data Analysis. Pre-stimulation baseline chronoampero-
metric currents were normalized to zero current values, with
induced changes in oxidation current, corresponding to changes in
dopamine efflux, presented as absolute changes in current
(increases as positive and decreases as negative). Changes in
dopamine efflux following intra-VTA morphine in wildtype and
M5 knockout mice, or following combinations of intra-VTA
morphine and intra-VTA scopolamine or systemic naltrexone in
wildtype mice were analyzed using mixed-model ANOVA.
Significant interactions were further analyzed using Fisher’s LSD
test.
Experiment 2: PPT-evoked striatal dopamine efflux in
wildtype and M5 knockout mice
Surgery. Surgical procedures and chronoamperometric
recordings followed those described for Experiment A single
concentric, bipolar stimulating electrode (SNE-100; Rhodes
Medical Co., Woodland Hills, CA) was implanted into the left
PPT of each mouse (A/P 20.5 mm from lambda, M/L 1.2 mm,
D/V 22.9 mm from dura) according to the atlas of Paxinos and
Franklin (2004), and a single stearate-modified carbon paste
electrode was implanted into the left striatum (A/P +1.4 mm from
bregma, M/L 1.5 mm, D/V 22.3 mm from dura). A
combination Ag/AgCl reference and stainless-steel auxiliary
electrode was placed into contact with the contralateral parietal
cortex.
PPT electrical stimulation. Following at least 30 min of
baseline recordings, a series of cathodal monophasic current pulses
(400 mA, 0.5 ms duration) were delivered to the concentric,
bipolar stimulating electrode implanted in the PPT via a
programmable pulse generator (Master-8; A.M.P.I., Jerusalem,
Israel) in combination with a constant current stimulus isolation
unit (Iso-Flex; A.M.P.I., Jerusalem, Israel). Each stimulation of the
PPT consisted of a 1 sec, 35 Hz train of 400 mA pulses (1 sec inter-
train interval) applied over a 60 sec period (1050 pulses in total).
These parameters were designed to mimic spontaneous firing
patterns of PPT neurons in awake, naturally aroused animals [37].
In urethane-anesthetized rats these stimulation parameters (at
800 mA) have been shown to evoke a tri-phasic pattern of striatal
dopamine efflux [18].
Systemic drug administration. Subsequent to monitoring
the effects of PPT stimulation on striatal dopamine efflux, a sub-set
of mice (4 wildtypes and 4 M5 knockouts) was injected with the
non-selective muscarinic receptor antagonist scopolamine hydro-
bromide (5 mg/kg, i.p.). Thirty min later, the PPT was again
stimulated and changes in striatal dopamine oxidation currents
were monitored for an additional 80 min.
Data analysis. Pre-stimulation baseline chronoamperometric
currents were normalized to zero current values, with stimulated
change in oxidation current, corresponding to changes in
dopamine efflux, presented as absolute changes in current
(increases as positive and decreases as negative). The maximal
and minimal PPT-evoked changes in dopamine efflux associated
with the two increases and the decrease, respectively, were
obtained for individual wildtype and M5 knockout mice. In the
case of the 8 mice that were pre-treated with scopolamine,
maximal and minimal PPT-evoked changes in dopamine efflux
after scopolamine were also obtained and compared to pre-
scopolamine PPT-evoked values. Mean peak efflux (in
nanoamperes, nA) and peak times (in min) were compared
between wildtype and M5 knockout mice (two-tailed unpaired t-
test) and before and after scopolamine in all mice (two-tailed
paired t-test). The peak time of the second increase in dopamine
efflux, which was strongly attenuated in M5 knockout mice, was
not statistically analyzed.
To calculate the overall M5 contribution to PPT-evoked striatal
dopamine efflux, the average PPT-evoked change in basal
dopamine oxidation current in M5 knockout mice was subtracted
from the average change in wildtype mice at each 30-sec time
point. The calculated differences were then plotted as a function of
time following PPT stimulation.
Histology
On completion of all experiments mice were killed with a
0.25 ml intracardial injection of urethane. Their brains were
removed and put into a 10% formalin solution. All brains were
then sectioned on a Vibratome, examined under a light
microscope, and compared to atlas sections (Paxinos and Franklin,
2004).
On completion Experiment 2, a PPT lesion was made by
passing direct current (100 mA for 5 sec) through the concentric
bipolar stimulating electrode. For these brains 0.1% potassium
ferricyanide was included in the formalin solution. The iron
deposited at the stimulating electrode tip by the electrolytic lesion
VTA Morphine and Accumbal Dopamine in M5 KO Mice
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spot, clearly marking the PPT stimulation site.
Drugs
Morphine sulfate pentahydrate, scopolamine hydrobromide,
naltrexone hydrochloride, and urethane were purchased from
Sigma Aldrich (St. Louis, MO) and dissolved in sterile 0.9% saline.
Drugs were infused into the VTA or systemically injected as their
salt weight. Intra-VTA infusions were made at a volume of 0.3 ml,
and systemic naltrexone and scopolamine injections at a volume of
10 ml/kg.
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